11th Jul 2016 12:00
SHIRE PLC - Holding(s) in CompanySHIRE PLC - Holding(s) in Company
PR Newswire
London, July 11
Holding(s) in Company
July 11, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Shire plc | |||
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||||
| An acquisition or disposal of voting rights | X | |||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
| An event changing the breakdown of voting rights | ||||
| Other (please specify): | Decrease in voting rights ownership due to company increase in shares outstanding | X | ||
| 3. Full name of person(s) subject to the notification obligation: iii | Harbor International Fund (a series of Harbor Funds, a Delaware Statutory Trust) | |||
| 4. Full name of shareholder(s) (if different from 3.):iv | ||||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | Trade Date: June 30, 2016 Settlement Date: July 5, 2016 | |||
| 6. Date on which issuer notified: | July 8, 2016 | |||
| 7. Threshold(s) that is/are crossed or reached: vi, vii | 3% of issuer’s voting rights | |||
| 8. Notified details: | |||||||||||||||||
| A: Voting rights attached to shares viii, ix | |||||||||||||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||||||||||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||||||||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||||||||
| Common SEDOL: B2QKY05 | 19,156,536 | 19,156,536 | 19,156,536 | 19,156,536 | N/A | 2.13% | N/A | ||||||||||
| B: Qualifying Financial Instruments | |||||||||||||||||
| Resulting situation after the triggering transaction | |||||||||||||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||||||||||||
| N/A | N/A | N/A | N/A | N/A | |||||||||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||||||||||||
| Resulting situation after the triggering transaction | |||||||||||||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | ||||||||||||
| N/A | N/A | N/A | N/A | N/A | Nominal | Delta | |||||||||||
| N/A | N/A | ||||||||||||||||
| Total (A+B+C) | |||||||||||||||||
| Number of voting rights | Percentage of voting rights | ||||||||||||||||
| 19,156,536 | 2.13% | ||||||||||||||||
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | ||
| N/A | ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | N/A | |
| 11. Number of voting rights proxy holder will cease to hold: | N/A | |
| 12. Date on which proxy holder will cease to hold voting rights: | N/A | |
| 13. Additional information: | Completed in Chicago, Illinois, USA on July 8, 2016 | |
| 14. Contact name: | Jodie L. Crotteau Assistant Secretary | |
| 15. Contact telephone number: | 312-443-4428 | |
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | [email protected] | +44 1256 894157 |
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
Related Shares:
Shire